Recent Updates for Industries

User Rating: 4 / 5

Star ActiveStar ActiveStar ActiveStar ActiveStar Inactive
 

Direktif untuk mengehadkan penggunaan colistin dalam keluaran ubat veterinar
published on 2019-04-18


Direktif untuk semua produk yang mengandungi fluoroquinolone (sediaan oral dan injeksi sahaja): Pengemaskinian sisip bungkusan dan risalah maklumat ubat untuk pengguna (RiMUP) dengan maklumat keselamatan berkaitan risiko aortic aneurysm dan aortic dissection
published on 2019-04-18


Direktif untuk semua produk yang mengandungi montelukast: pengemaskinian sisip bungkusan dan risalah maklumat ubat untuk pengguna (RiMUP) dengan penambahan maklumat keselamatan berkaitan risiko obsessive-compulsive symptoms
published on 2019-04-18


Public Consultation On Implementation Of Bioequivalence (BE) Study Requirements For New Drug Products Containing Scheduled Poison
published on 2019-04-16


NPRA Customer Satisfaction Survey
published on 2019-04-15


Kenyataan Akhbar KPK 29 Mac 2019 -Produk Losartan yang ditarik Balik di Singapura Serta Situasi di Pasaran Malaysia
published on 2019-04-12


New Products Approved
published on 2019-04-10


Kenyataan Akhbar KPK 5 April 2019 – Panggil Balik ke atas Produk Tradisional Mengandungi Paras Logam Berat yang Tinggi
published on 2019-04-09


Carbimazole and methimazole (thiamazole): (i) Risk of birth defects and neonatal disorders in case of exposure during pregnancy; (ii) Risk of pancreatitis
published on 2019-04-09


Additional Indications Approved
published on 2019-04-08


Oral retinoids: Risk of neuropsychiatric symptoms
published on 2019-04-04


Tapentadol: Risk of seizures and reports of serotonin syndrome when co-administered with other drugs
published on 2019-04-04


KPK Press Release 1 April 2019-Cosmetic Products Found To Contain Scheduled Poison
published on 2019-04-02


Direktif untuk melaksanakan Guidelines on facilitated registration pathway: abbreviated and verification review
published on 2019-03-28


Direktif untuk semua produk yang mengandungi retinoid (oral): Pengemaskinian sisip bungkusan dan risalah maklumat ubat untuk pengguna (RiMUP) dengan maklumat keselamatan berkaitan neuropsychiatric disorders
published on 2019-03-27


Direktif untuk semua produk yang mengandungi noradrenaline: Pengemaskinian sisip bungkusan dengan maklumat keselamatan berkaitan stress cardiomyopathy
published on 2019-03-27


Announcement Of Online Appeal Application For Product Rejected By DCA
published on 2019-03-21


Reminder: Implementation of Regulatory Control of Active Pharmaceutical Ingredients (API) For Registered Products with Registration Expiration Starting 1 January 2020
published on 2019-03-19


List of Renewal Approved Veterinary Products
published on 2019-03-19


About myGovXchange Online Payment Service Provided by MAMPU
published on 2019-03-19


Kenyataan Akhbar KPK 18 Mac 2019 – Produk Tradisional Nan Bao Capsule Dikesan Mengandungi Racun Berjadual Sildenafil Dan Tadalafil
published on 2019-03-18


MADRAC Members
published on 2019-03-16


Xylometazoline: Increased Risk of Serious Ventricular Arrhythmia in Patients with Long QT Syndrome
published on 2019-03-15


Direct-Acting Antivirals (DAAVs) : Risk of Hypoglycaemia in Patients with Diabetes
published on 2019-03-15


4.4 : Post-Marketing Activities
published on 2019-03-13


Generic Product List For BE Studies
published on 2019-03-04


New Chemical Entities
published on 2019-02-28


QUEST3+ Scheduled Maintenance
published on 2019-02-26


Pending Payment Expiring Period
published on 2019-02-25


Online Public Engagement
published on 2019-02-22


Seranta Awam Atas Talian
published on 2019-02-21


Organisation Chart
published on 2019-02-15


Penjualan Produk Herba Untuk Memulih & Mencegah Demam Denggi
published on 2019-02-13


Kenyataan Akhbar Kementerian Kesihatan Malaysia : Produk Tradisional Nan Bao (Capsule) Dikesan Mengandungi Racun Berjadual Sildenafil
published on 2019-02-12


25PPWG ANNEX 7 (iv) Final ASEAN Guideline on Stability Study Drug Product R2
published on 2019-02-12


MOPI Training - International Good Manufacturing Training Program 2019
published on 2019-02-04


Berita Ubat-Ubatan Disember 2018
published on 2019-02-04


The 27th ASEAN Consultative Committee for Standards and Quality
published on 2019-01-31


Direktif Untuk Menerima Permohonan Lesen Import Percubaan Klinikal (CTIL) Dan Kebenaran Untuk Mengilang Produk Tidak Berdaftar Untuk Tujuan Percubaan Klinikal (CTX) Yang Melibatkan First-In-Human
published on 2019-01-29


Verification of Translated Official Documents
published on 2019-01-23


Data Exclusivity
published on 2019-01-23


Direktif untuk semua produk yang mengandungi Lamotrigine :Pengemaskinian sisip bungkusan dan risalah maklumat ubat untuk pengguna (RiMUP) dengan maklumat keselamatan berkaitan risiko hemophagocytic lymphohistiocytosis (HLH)
published on 2019-01-18


Direktif untuk semua produk antibiotik beta-lactam termasuk kombinasi: Pengemaskinian sisip bungkusan dan risalah maklumat ubat untuk pengguna (RiMUP) dengan maklumat keselamatan severe cutaneous adverse reactions (SCARs)
published on 2019-01-18


Drug Registration Guidance Document : Second Edition – September 2016, revised January 2019
published on 2019-01-17


Guidance Document on Verification of Translated Official Document - Januari 2019
published on 2019-01-16


Direktif Untuk Penggunaan Drug Registration Guidance Document (DRGD) Second Edition, September 2016, Revised January 2019
published on 2019-01-14


Garispanduan Pelaksanaan Risalah Maklumat Ubat Untuk Pengguna (RiMUP)
published on 2019-01-09


Internet Browser for QUEST3+ System
published on 2019-01-09


List of Registered Veterinary Products
published on 2019-01-08


Online Payment Service Notice
published on 2019-01-07


Comments (0)

There are no comments posted here yet

Leave your comments

Posting comment as a guest.
0 Characters
Attachments (0 / 3)
Share Your Location

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Newsletter Subsription

Site Last Modified

  • Last Modified: Friday 19 April 2019, 08:48:21.
© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language